Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Adebrelimab + Apatinib + S-1 in HER2+ Gastric Cancer
NCT06385873Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2024
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of disitamab vedotin in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Jiangsu Provincial People's Hospital. Planned start May 2024; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06385873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06385873.